This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TNFRSF12A / Tumor necrosis factor receptor superfamily member 12A · IHC design guide
Design Immunohistochemistry for TNFRSF12A
Plan TNFRSF12A IHC in paraffin sections using placental trophoblasts as a high-staining reference (HPA tissue IHC). Assess cytoplasmic and membranous staining by cell type and intensity, bearing in mind its low consistency with RNA expression (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TNFRSF12A Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous tissue staining (HPA tissue IHC) | |
| Staining pattern | Placental trophoblasts stain strongly; cytoplasmic and membranous (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Placenta+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06261) | |
| Caveat | Antibody staining shows low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Expression varies across tissues (UniProt) | |
| Isoform / epitope | 2 isoforms; check extracellular vs cytoplasmic epitopes (UniProt) |
Section 1
Recommended TNFRSF12A IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published protocols for mouse gastrocnemius muscle (PMC11790590) and human tissue sections (PMC11810735).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A06261); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-TNFRSF12A, 1:100–1:500 starting range (standard) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TNFRSF12A-positive staining in trophoblastic cells of placenta (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page antigen retrieval); the mouse protocol also used citric acid retrieval (PMC11790590).
Section 2
What Is the Expected TNFRSF12A Staining Pattern?
TNFRSF12A is a membrane receptor with an extracellular segment at residues 28–80 and a transmembrane segment at 81–101 (UniProt Q9NP84 topology). In tissue sections, expect membranous and cytoplasmic staining, especially strong staining in placental trophoblastic cells (HPA: tissue IHC). Interpret intensity cautiously: the HPA tissue profile is Approved but has low consistency between antibody staining and RNA expression (HPA: reliability description).
| Placental trophoblastic cells show strong membranous staining with some cytoplasmic signal. | This fits the strongest listed cell-level result: trophoblastic cells are High in placenta (HPA: tissue IHC). Cytoplasmic and membranous staining also fits the reported tissue profile (HPA: tissue IHC). |
| Signal is predominantly nuclear, with little discernible membrane or cytoplasmic staining. | A nuclear-only pattern is unsupported by the membrane topology (UniProt Q9NP84 topology) and by HPA's cytoplasmic and membranous tissue profile (HPA: tissue IHC). Check controls and staining conditions before interpreting it as TNFRSF12A. |
| Strong staining appears in colon glandular cells or soft-tissue fibroblasts. | Both cell populations are listed as Not detected (HPA: tissue IHC). Consider cross-reactivity or endogenous chromogenic activity, then compare the staining with a negative-primary control (general IHC practice). |
| Color is widespread across the section without clear cell boundaries. | This is difficult to score as a membranous or cytoplasmic pattern (HPA: tissue IHC). Diffuse staining can reflect nonspecific detection or background; inspect the negative-primary control and tissue morphology (general IHC practice). |
| Placental trophoblastic cells have no detectable signal. | A negative result conflicts with their High HPA staining level (HPA: tissue IHC), but does not alone establish absent protein. First assess tissue preservation, the positive control and the IHC detection run (general IHC practice). |
💡Expected TNFRSF12A appearanceCall a section positive when the relevant cells show interpretable membranous and cytoplasmic signal, with High staining expected in placental trophoblastic cells (HPA: tissue IHC); isolated nuclear signal or strong staining in listed Not detected cells warrants investigation (UniProt Q9NP84 topology; HPA: tissue IHC).
| Which compartment should guide scoring? | TNFRSF12A spans the membrane at residues 81–101 (UniProt Q9NP84 topology). HPA reports cytoplasmic and membranous tissue staining, so assess both patterns in the named cells (HPA: tissue IHC). |
| Which tissues best frame intensity? | Placental trophoblastic cells are High; adrenal glandular, bronchial respiratory epithelial and marrow hematopoietic cells are Medium (HPA: tissue IHC). These are cell-specific observations, not a uniform whole-tissue score. |
| How strong is the validation? | HPA lists antibody HPA007853 as Approved for IHC, while its tissue profile notes low staining–RNA consistency (HPA: antibodies; HPA: reliability description). Approved should not be described as Enhanced. |
| Does processing explain a missing compartment? | UniProt annotates removal of the 1–27 signal peptide and a 28–129 chain (UniProt Q9NP84 processing). The supplied record gives no antibody epitope, so it cannot establish which region is detected. |
| Can isoforms or retrieval predict intensity? | Two isoforms are listed (UniProt Q9NP84 isoforms). Their tissue staining and recognition by this antibody are unspecified; no target-specific antigen-retrieval or fixation effect is established by these sources. |
| IF/ICC Q&A: where should signal appear? | Plasma membrane and cytosol are Approved locations in HPA ICC-IF (HPA: subcellular). Use that localisation to interpret IF/ICC images; the staining guidance here concerns chromogenic IHC in paraffin sections. |
| Situation | Likely cause | Next action |
|---|---|---|
| Placenta is negative or much weaker than expected (HPA: High in trophoblastic cells). | The control may lack evaluable trophoblastic cells, or the IHC run may have failed (general IHC practice). HPA intensity alone cannot identify the cause. | Confirm the cell population on the counterstained section; review the positive control, negative-primary control, detection reagents and run records (general IHC practice). |
| Strong signal appears in colon glandular cells (HPA: Not detected). | Cross-reactivity or endogenous chromogenic activity is possible (general IHC practice); the HPA profile has low staining–RNA consistency (HPA: reliability description). | Compare a negative-primary control and tissue morphology; assess whether the signal follows cells, edges or background before assigning cell-level positivity (general IHC practice). |
| Signal is mainly nuclear (HPA: cytoplasmic and membranous tissue profile). | The compartment disagrees with the annotated membrane receptor topology (UniProt Q9NP84 topology). Nonspecific staining or scoring error is possible (general IHC practice). | Recheck the compartment against the counterstain and negative-primary control; score membrane and cytoplasm separately from nuclei (general IHC practice). |
| The entire section has diffuse chromogenic color. | Excess background can obscure cell-level localisation (general IHC practice); HPA's reported pattern requires readable cytoplasmic and membranous staining (HPA: tissue IHC). | Inspect the negative-primary control and detection background; review blocking, washing and detection conditions within the established IHC workflow (general IHC practice). |
| Adipocytes stain strongly in adipose tissue or breast. | Adipocytes are Not detected in both listed tissues (HPA: tissue IHC). Apparent signal may reflect background or mistaken assignment to adjacent cells (general IHC practice). | Identify the stained cell type on the counterstain, compare the negative-primary control and avoid scoring color outside adipocyte boundaries as adipocyte staining (general IHC practice). |
| Placenta is positive, but lung alveolar cells are faint. | This may match the observed range: trophoblastic cells are High and alveolar cells are Low (HPA: tissue IHC). The difference alone does not establish a technical failure. | Score the named cell populations separately and compare them with their own HPA levels; document unexpected compartments or background alongside intensity (HPA: tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing TNFRSF12A staining
A06261 · IHCImmunohistochemistry of Fn14 in human liver tissue with Fn14 antibody at 2.5 μg/mL.
A06261 · IFImmunofluorescence of Fn14 in Human Liver cells with Fn14 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000006327-TNFRSF12A/tissue/cerebral+cortex#imid_2365848
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000006327-TNFRSF12A/tissue/colon#imid_2365774
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000006327-TNFRSF12A/tissue/liver#imid_2365791
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000006327-TNFRSF12A/tissue/kidney#imid_2365792
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA007853; green = TNFRSF12A, blue = nucleus, red = microtubules.
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA007853; green = TNFRSF12A, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TNFRSF12A IHC & IF
🧪Run placenta first: trophoblastic cells should stain (HPA: High in trophoblastic cells). Use colon glandular cells as the negative tissue (HPA: Not detected in colon glandular cells); on the placenta slide, use only cells verified to lack target staining as internal negatives, with background-level chromogen (standard IHC practice).
Positive control tissue: Placenta (Trophoblastic cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show TNFRSF12A in U-251MG, U2OS, with annotated localisation: Plasma membrane (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, an isotype control matched to the primary antibody’s host species, immunoglobulin class and clonality, and a TNFRSF12A knockout control or peptide block if the immunizing peptide is available (standard IHC practice). Quench endogenous peroxidase in placenta and block endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: No target-specific fixation window, fixation effect or antigen-retrieval dependency is reported in the supplied evidence; the A06261 human-liver IHC caption gives 2.5 µg/mL but does not report a fixative (caption: A06261). Optimize retrieval empirically for paraffin sections; the evidence does not establish whether frozen sections or IF/ICC are easier (standard IHC practice; HPA: ICC-IF images in U-251MG and U2OS). Placental blood cells can contribute endogenous peroxidase background, so interpret staining against the quenched no-primary control (standard IHC practice).
HPA tissue IHC evidence for TNFRSF12A
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Placenta | Trophoblastic cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Colon | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Small intestine | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced TNFRSF12A IHC Tips
Troubleshoot TNFRSF12A staining in paraffin sections by checking retrieval, compartment, cell identity and controls before comparing signal across samples.
What retrieval should I start with for TNFRSF12A in paraffin sections?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page retrieval specification). If staining is weak, compare an adjacent section after a modest change in heating time, keeping the antibody concentration and detection steps constant; inspect tissue morphology before accepting a stronger signal (standard IHC practice). TNFRSF12A has an extracellular region at residues 28–80 and a cytoplasmic region at 102–129, so epitope accessibility depends on the antibody’s binding site (UniProt Q9NP84 topology). Score membrane and cytoplasmic staining separately, since both patterns have been reported in tissue IHC (HPA tissue IHC profile).
How should I troubleshoot weak staining when fixation conditions differ between samples?
Target-specific sensitivity to fixation is unknown from the supplied evidence; the selected antibody’s liver IHC caption does not state a fixative (A06261 tissue-IHC caption). Record the fixative, time to fixation and fixation duration for each sample, then compare sections processed with the same retrieval and detection conditions (standard IHC practice). If staining differs, test matched sections with consistent processing before attributing the difference to TNFRSF12A abundance (standard IHC practice). Preserve morphology when adjusting retrieval, and interpret weak signal alongside a positive control and a no-primary control run in the same batch (standard IHC practice).
Should TNFRSF12A staining appear at the membrane or in the cytoplasm?
Examine membrane staining and cytoplasmic staining as separate observations: TNFRSF12A is a membrane protein with a transmembrane segment at residues 81–101 (UniProt Q9NP84 topology), while tissue IHC reports both patterns (HPA tissue IHC profile). Annotate which cells carry each pattern rather than assigning a whole section one localisation score (standard IHC practice). Cytoplasmic staining alone needs careful control review, because the reported IHC profile does not establish that every cytoplasmic signal is specific (HPA tissue IHC profile). Compare the same compartment in positive controls and test sections under identical detection and counterstaining conditions (standard IHC practice).
Can one antibody distinguish the two TNFRSF12A isoforms in tissue sections?
TNFRSF12A has 2 annotated isoforms, but the supplied evidence does not map the catalog antibody’s epitope to an isoform (UniProt Q9NP84 isoforms; A06261 tissue-IHC caption). Do not assign an isoform from chromogenic staining alone without an antibody epitope map and independent isoform-specific evidence (standard IHC interpretation). The reference topology places the extracellular region at residues 28–80 and the cytoplasmic region at 102–129, which matters when assessing whether an epitope could remain accessible after processing (UniProt Q9NP84 topology). Document the antibody identifier and any verified epitope information alongside the staining result (standard IHC practice).
How can I adapt the localisation check to multiplex IF?
Use multiplex IF to compare TNFRSF12A with a validated marker for the expected cell type in the specimen, and assess colocalisation at cell boundaries rather than relying on overlap in a projection (standard IF practice; UniProt Q9NP84 membrane annotation). Choose a fluorophore channel that separates specific signal from the specimen’s autofluorescence, checking an unstained section first (standard IF practice). Match permeabilisation to the verified epitope: a cytoplasmic-tail epitope requires access inside the cell, whereas an extracellular epitope may be assessed before permeabilisation (UniProt Q9NP84 topology; standard IF practice). Report membrane and cytosolic patterns separately, since both locations are listed for TNFRSF12A in ICC/IF (HPA subcellular profile).
What should I check when the DAB signal is diffuse or widespread?
Run a no-primary control and verify the peroxidase block when diffuse DAB staining obscures cell boundaries (standard chromogenic IHC practice). Review whether signal follows section edges, damaged areas or the distribution of endogenous pigment rather than intact cell contours (standard IHC practice). Compare antibody dilution and detection time on adjacent sections, changing one variable at a time while retaining the same counterstain (standard IHC practice). Widespread staining is not automatically false: tissue IHC describes TNFRSF12A as cytoplasmic and membranous in many tissues, with low consistency between antibody staining and RNA expression (HPA tissue IHC profile; HPA reliability description).
How should I score TNFRSF12A staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, then record the percentage of positive cells and staining intensity for an H-score (standard IHC scoring practice; HPA tissue IHC profile). If cell numbers vary, report positive cells per mm² of viable tissue or per defined cell population, using the same rule for every section (standard image analysis practice). Normalise to the number of evaluable cells or viable tissue area, and exclude folds and necrotic regions using a prespecified rule (standard IHC scoring practice). Keep membrane and cytoplasmic scores separate because both staining patterns are reported for TNFRSF12A (HPA tissue IHC profile).
How can I distinguish a convincing TNFRSF12A signal from artefact?
A convincing result follows identifiable cells and shows a reproducible membrane or cytoplasmic pattern, the patterns reported for TNFRSF12A in tissue IHC (HPA tissue IHC profile; standard IHC interpretation). Check cell identity against an appropriate marker or morphology, since the HPA reports high staining in placental trophoblastic cells but no detection in colonic glandular cells (HPA tissue IHC). Treat staining concentrated at section edges or in necrotic areas as suspect, and inspect the no-primary control for endogenous enzyme signal (standard IHC practice). Interpret discordant samples cautiously because HPA labels its tissue IHC reliability Approved while reporting low consistency with RNA expression (HPA reliability description).
Boster reagents
Best TNFRSF12A / Tumor necrosis factor receptor superfamily member 12A IHC Antibodies
A06261 has human liver tissue IHC and human liver cell IF images (catalog image captions). M06261 lists IHC reactivity for human, mouse and rat (catalog applications/reactivity).
Real IHC data
Anti-Fn14 TNFRSF12A Antibody
Cat # A06261
The rendered SKU is A06261, listed for human IHC-P and IF (catalog applications/reactivity). Its images show IHC in human liver tissue at 2.5 μg/mL and IF in human liver cells at 20 μg/mL (A06261 image captions).
Which to pick: Choose A06261 for human paraffin-section IHC: IHC-P is listed, and its own image shows staining in human liver tissue; the fixative is unreported (A06261 applications/IHC image caption). For IF, choose A06261 based on its human liver cell image; ICC preparation is unspecified (A06261 IF image caption). For mouse or rat IHC, M06261 lists those species and IHC and is rabbit monoclonal, but has no IHC image or listed IF application (M06261 catalog reactivity/applications/clone/image alts).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9NP84 (TNR12_HUMAN, Tumor necrosis factor receptor superfamily member 12A).
- Human Protein Atlas. TNFRSF12A tissue IHC expression (reliability: Approved).
- Human Protein Atlas. TNFRSF12A subcellular location (ICC-IF): Localized to the plasma membrane and cytosol..
- Human Protein Atlas. TNFRSF12A antibody validation summary (1 antibodies).
- Melatonin Ameliorates Age-Related Sarcopenia via the Gut-Muscle Axis Mediated by Serum Lipopolysaccharide and Metabolites. Journal of cachexia, sarcopenia and muscle 2025 — PMC11790590.
- A Transcriptomic Analysis of Cancer-Stromal Interactome in Lung Cancer Xenograft Models. Cancer science 2026 — PMC12951093.
- Identification of WDR74 and TNFRSF12A as biomarkers for early osteoarthritis using machine learning and immunohistochemistry. Frontiers in immunology 2025 — PMC11810735.
- A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma. Frontiers in oncology 2021 — PMC8085360.
- PubMed PMID:10751351 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:11728344 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TNFRSF12A (Tumor necrosis factor receptor superfamily member 12A). Expected localisation Cytoplasmic and membranous tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A06261 at 1:100–1:500 (standard starting range) (the product's own IHC validation image is shown). Controls (HPA): positive Placenta (Trophoblastic cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A06261); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-TNFRSF12A, 1:100–1:500 starting range (standard); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06261); Caveat: Antibody staining shows low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; check extracellular vs cytoplasmic epitopes (UniProt); Regulation: Expression varies across tissues (UniProt). Evidence: UniProt Q9NP84, HPA tissue IHC · Approved, HPA ICC-IF · plasma membrane and cytosol., Datasheet A06261, PMC11790590, PMC11810735. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TNFRSF12A/immunohistochemistry-ihc-guide.